Assignee
CHEMOCENTRYX INC
US·195 granted patents·79 pending applications·1,369 citations·filing 2000–2025
Top patents by PatentIndex Score
274 records- 0199US7884110B2Fused heteroaryl pyridyl and phenyl benzenesuflonamides as CCR2 modulators for the treatment of inflammationCHEMOCENTRYX INC·Filed 2008·Granted Feb 8, 2011·41 cites·6 claims
- 0298US11426364B2Immunomodulator compoundsCHEMOCENTRYX INC·Filed 2020·Granted Aug 30, 2022·10 cites·6 claims
- 0398US9834545B2Modulators of chemokine receptorsCHEMOCENTRYX INC·Filed 2016·Granted Dec 5, 2017·26 cites·33 claims
- 0498US7622583B2Heteroaryl sulfonamides and CCR2CHEMOCENTRYX INC·Filed 2006·Granted Nov 24, 2009·106 cites·5 claims
- 0597US11485708B2Compounds for treatment of PD-L1 diseasesCHEMOCENTRYX INC·Filed 2020·Granted Nov 1, 2022·9 cites·21 claims
- 0697US11266643B2Triaryl compounds for treatment of PD-L1 diseasesCHEMOCENTRYX INC·Filed 2020·Granted Mar 8, 2022·13 cites·32 claims
- 0797US11135210B2Indane-amines as PD-L1 antagonistsCHEMOCENTRYX INC·Filed 2020·Granted Oct 5, 2021·10 cites·23 claims
- 0897US11045469B2Compositions and methods for treating inflammatory bowel disease using a combination therapy of small molecule inhibitors of C-C chemokine receptor type 9 (CCR9) and anti-α4β7 integrin blocking antibodiesCHEMOCENTRYX INC·Filed 2020·Granted Jun 29, 2021·5 cites·18 claims
- 0997US10639284B2Immunomodulator compoundsCHEMOCENTRYX INC·Filed 2017·Granted May 5, 2020·17 cites·30 claims
- 1097US10035768B2C5aR antagonistsCHEMOCENTRYX INC·Filed 2017·Granted Jul 31, 2018·23 cites·10 claims
- 1197US9809581B2Inhibitors of CXCR2CHEMOCENTRYX INC·Filed 2016·Granted Nov 7, 2017·23 cites·29 claims
- 1297US9745312B2Fused heteroaryl pyridyl and phenyl benzenesuflonamides as CCR2 modulators for the treatment of inflammationCHEMOCENTRYX INC·Filed 2016·Granted Aug 29, 2017·13 cites·19 claims
- 1397US9573897B2C5AR antagonistsCHEMOCENTRYX INC·Filed 2015·Granted Feb 21, 2017·24 cites·9 claims
- 1496US11713307B2Heteroaryl-biphenyl amides for the treatment of PD-L1 diseasesCHEMOCENTRYX INC·Filed 2020·Granted Aug 1, 2023·8 cites·28 claims
- 1596US11691985B2Macrocyclic immunomodulatorsCHEMOCENTRYX INC·Filed 2021·Granted Jul 4, 2023·4 cites·20 claims
- 1696US11478460B2Diaryl substituted 6,5-fused ring compounds as C5aR inhibitorsCHEMOCENTRYX INC·Filed 2020·Granted Oct 25, 2022·3 cites·34 claims
- 1796US11059834B2Macrocyclic immunomodulatorsCHEMOCENTRYX INC·Filed 2019·Granted Jul 13, 2021·10 cites·18 claims
- 1896US11026935B2Free base crystalline form of a complement component C5a receptorCHEMOCENTRYX INC·Filed 2020·Granted Jun 8, 2021·5 cites·9 claims
- 1996US10919852B2Immunomodulator compoundsCHEMOCENTRYX INC·Filed 2018·Granted Feb 16, 2021·15 cites·25 claims
- 2096US10568874B2Indane-amines as PD-L1 antagonistsCHEMOCENTRYX INC·Filed 2019·Granted Feb 25, 2020·13 cites·26 claims
- 2196US10562896B26-5 fused rings as C5a inhibitorsCHEMOCENTRYX INC·Filed 2018·Granted Feb 18, 2020·11 cites·38 claims
- 2296US9394307B2Fused heteroaryl pyridyl and phenyl benzenesuflonamides as CCR2 modulators for the treatment of inflammationCHEMOCENTRYX INC·Filed 2013·Granted Jul 19, 2016·15 cites·19 claims
- 2396US8906938B2C5aR antagonistsCHEMOCENTRYX INC·Filed 2013·Granted Dec 9, 2014·28 cites·5 claims
- 2495US11708326B2Immunomodulator compoundsCHEMOCENTRYX INC·Filed 2020·Granted Jul 25, 2023·4 cites·25 claims
- 2595US10792360B1Compositions and methods for treating inflammatory bowel disease using CCR9 inhibitor and anti-TNF-alpha blocking antibodiesCHEMOCENTRYX INC·Filed 2020·Granted Oct 6, 2020·6 cites·16 claims
- 2695US10660897B2C5aR antagonistsCHEMOCENTRYX INC·Filed 2018·Granted May 26, 2020·6 cites·5 claims
- 2795US10583131B2Methods of treating pancreatic cancerCHEMOCENTRYX INC·Filed 2019·Granted Mar 10, 2020·8 cites·21 claims
- 2895US9783540B2Substituted tetrahydropyrans as CCR2 modulatorsCHEMOCENTRYX INC·Filed 2016·Granted Oct 10, 2017·7 cites·45 claims
- 2995US7718683B2Triazolyl phenyl benzenesulfonamidesCHEMOCENTRYX INC·Filed 2007·Granted May 18, 2010·39 cites·4 claims
- 3095US6559160B1Compounds and methods for modulating cxcr3 functionCHEMOCENTRYX INC·Filed 2000·Granted May 6, 2003·73 cites·22 claims
- 3194US11142521B2Substituted anilines as CCR(4) antagonistsCHEMOCENTRYX INC·Filed 2019·Granted Oct 12, 2021·4 cites·6 claims
- 3294US10683294B25-5 fused rings as C5a inhibitorsCHEMOCENTRYX INC·Filed 2018·Granted Jun 16, 2020·8 cites·31 claims
- 3394US10464934B2Substituted tetrahydropyrans as CCR2 modulatorsCHEMOCENTRYX INC·Filed 2017·Granted Nov 5, 2019·5 cites·13 claims
- 3494US10398685B2Methods of treating pancreatic cancerCHEMOCENTRYX INC·Filed 2019·Granted Sep 3, 2019·6 cites·20 claims
- 3594US10370363B2Inhibitors of CXCR2CHEMOCENTRYX INC·Filed 2017·Granted Aug 6, 2019·6 cites·13 claims
- 3694US10336736B2Modulators of chemokine receptorsCHEMOCENTRYX INC·Filed 2017·Granted Jul 2, 2019·6 cites·24 claims
- 3794US10329314B2Soluble C5aR antagonistsCHEMOCENTRYX INC·Filed 2018·Granted Jun 25, 2019·12 cites·21 claims
- 3894US9745268B2Processes and intermediates in the preparation of C5aR antagonistsCHEMOCENTRYX INC·Filed 2015·Granted Aug 29, 2017·11 cites·31 claims
- 3994US7790726B2Monocyclic and bicyclic compounds and methods of useCHEMOCENTRYX INC·Filed 2006·Granted Sep 7, 2010·34 cites·7 claims
- 4094US7262204B2Modulation of CCR4 functionCHEMOCENTRYX INC·Filed 2003·Granted Aug 28, 2007·87 cites·18 claims
- 4193US11479553B25-5 fused rings as C5a inhibitorsCHEMOCENTRYX INC·Filed 2020·Granted Oct 25, 2022·3 cites·24 claims
- 4293US11384079B26-5 fused rings as C5a inhibitorsCHEMOCENTRYX INC·Filed 2019·Granted Jul 12, 2022·5 cites·18 claims
- 4393US10828285B2Diaryl substituted 6,5-fused ring compounds as C5aR inhibitorsCHEMOCENTRYX INC·Filed 2018·Granted Nov 10, 2020·5 cites·27 claims
- 4493US10392405B2Macrocyclic immunomodulatorsCHEMOCENTRYX INC·Filed 2018·Granted Aug 27, 2019·13 cites·46 claims
- 4593US10266492B2Processes and intermediates in the preparation of C5aR antagonistsCHEMOCENTRYX INC·Filed 2017·Granted Apr 23, 2019·8 cites·10 claims
- 4693US10251888B2Method of treating pancreatic cancerCHEMOCENTRYX INC·Filed 2017·Granted Apr 9, 2019·9 cites·8 claims
- 4793US7807704B2Bicyclic, nitrogen-containing compounds modulating CXCR4 and/or CCXCKR2CHEMOCENTRYX INC·Filed 2007·Granted Oct 5, 2010·30 cites·18 claims
- 4893US7582661B2Aryl sulfonamidesCHEMOCENTRYX INC·Filed 2005·Granted Sep 1, 2009·18 cites·17 claims
- 4992US11485737B2Diaryl substituted 5,5-fused ring compounds as C5aR inhibitorsCHEMOCENTRYX INC·Filed 2020·Granted Nov 1, 2022·2 cites·29 claims
- 5092US11382915B2Treatment of focal segmental glomerulosclerosis with CCR2 antagonistsCHEMOCENTRYX INC·Filed 2020·Granted Jul 12, 2022·2 cites·20 claims
Showing the top 50 of 274 patent records by PatentIndex Score.
Counts cover granted patents and pending applications in the PatentIndex corpus. How scoring works →